What Can Korean Pharma Do Right To Build R&D, Alliances?
This article was originally published in PharmAsia News
Executive Summary
What is an ideal R&D business model for the South Korean pharma industry and what are some of the key factors that could lead to successful novel research? At a recent meeting in Seoul, executives from leading domestic pharma companies including Yuhan and Hanmi shared their views and experience on how to develop valuable assets and seal successful international licensing deals.
You may also be interested in...
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.